Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 43

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
077,844 shares issued and 46,240,604 shares outstanding at December 31, 202448 47 Treasury stock, at cost, inclusive of excise tax and broker fees, 4,769,346 and 837,240 shares at September 30, 2025 and December 31, 2024, respectively(125,543)(25,121)     Additional paid-in capital1,049,545 1,009,435      Accumulated deficit(200,959)(206,356)     Accumulated other comprehensive income4,123 343           Total stockholders’ equity727,214 778,348           Total liabilities and stockholders’ equity$1,297,577 $1,553,516  

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  2

Table of Contents

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2025202420252024Revenues:    Net product sales$178,040 $167,722 $525,981 $509,933 Royalty revenue1,476 851 3,557 3,780           Total revenues179,516 168,573 529,538 513,713 Operating expenses:    Cost of goods sold34,278 38,864 109,450 130,542 Research and development25,966 19,104 79,859 57,680 Selling, general and administrative91,797 74,333 267,151 214,485 Amortization of acquired intangible assets14,322 14,322 42,966 42,966 Goodwill impairment— 163,243 — 163,243 Contingent consideration charges (gains), acquisition-related expenses, restructuring and other6,791 (1,766)13,261 2,872           Total operating expenses173,154 308,100 512,687 611,788 Income (loss) from operations6,362 (139,527)16,851 (98,075)Other income (